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ABSTRACT The size of lentiviral DNA reservoirs reﬂects the effectiveness of immune
responses against lentiviruses. So far, abundant information has been gathered on
the control of HIV-1 replication. Understanding the innate mechanisms contributing
to containment of the HIV DNA reservoir, however, are only partly clariﬁed and are
relevant to guiding interventions for reservoir containment or eradication. We stud-
ied the contribution of natural killer (NK) cell functional features in HIV patients con-
trolling replication either spontaneously (HIV controllers [HIC]) or after progression
and antiretroviral treatment (progressor patients [PP]). An inverse correlation be-
tween HIV DNA copy numbers (either total or integrated) in circulating CD4 cells
and NK cell function was observed. Induced interferon gamma (IFN-) production
and NKp46/NKp30 activating receptor-induced expression correlated inversely with
reservoir size. The correlation was present not only for a homogeneous cohort of
HIC patients but also when PP were included in the analysis. Adaptive (NKG2C
CD57) NK cell features were not associated with reservoir size. However, a distinct
set of 370 differentially expressed transcripts was found to underlie functional differ-
ences in NK cells controlling HIV DNA reservoir size. In proof-of-principle in vitro
experiments of CD4 cell infection with HIV-1, puriﬁed NK cells with the above-
mentioned functional/transcriptional features displayed 10- and 30-fold higher abili-
ties to control HIV replication and DNA burdens in vitro, respectively, than those of
other NK cells. Thus, NK cells with a speciﬁc functional and transcriptional signature
contribute to control of the HIV reservoir in CD4 cells. Their selection, expansion,
and/or adoptive transfer may support strategies to eradicate HIV-1 infection or to
safely deescalate antiretroviral treatment.
IMPORTANCE The most relevant feature of HIV-1 infection is represented by its
DNA reservoir size in the body, which guarantees lifelong infection and resumption
of virus replication after antiretroviral treatment interruption. So far, there has been
little success in the identiﬁcation of factors contributing to HIV-1 reservoir contain-
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ment. In this study, by studying quantitative total and integrated HIV-1 DNA levels
and NK cells in HIV-1 patients with either progressive or nonprogressive disease, we
observed that inducible IFN- and natural cytotoxicity receptor (NCR) expression in a
speciﬁc subset of NK cells with a characteristic transcriptional signature represents a
correlate for HIV-1 reservoir control. This represents an advance in our understand-
ing of the mechanism(s) that controls the lentivirus reservoir. Monitoring, selection,
expansion, and adoptive transfer of these NK cells may allow monitoring of treat-
ment efﬁcacy and the likelihood of reservoir control and may support protocols for
HIV-1 eradication.
KEYWORDS DNA, HIV-1, reservoir, interferons, lentiviruses, natural killer cells
Since their original description as cells endowed with cytotoxic antitumor activityand CD16 and CD56 antigen expression (1–4), our view of natural killer (NK) cells
has been upgraded with a number of additional functions, including a ﬁnely tuned
balance between activating natural cytotoxicity receptor (NCR; NKp46, NKp30, and
NKp44) function and inhibitory killer Ig-like inhibitory receptor (KIR) function, cytokine
production and responsiveness, Toll-like receptor (TLR) and chemokine receptor ex-
pression, and identiﬁcation of NK cell developmental stages from CD34 cell precursors
(5–12). In addition, a quite remarkable heterogeneity of circulating NK cell phenotypes
has been revealed by mass cytometry (13) and computer-assisted ﬂow cytometric
analysis (14).
Similarly, the original view of prevalent NK cell antitumor activity has evolved to
encompass the fundamental role of these cells in the control of virus infections. Indeed,
NK cell absence in humans, or their removal in mice, leads to disseminated herpesvirus,
inﬂuenza virus, and Ebola virus infections (15–18). Their relevance in control of virus
infections is reﬂected by the quantity of mechanisms that have been developed to
evade NK cell activity, including skewed cytokine production (19, 20), reduced NCR
expression with an activated NK cell phenotype (21–23), and NCR ligand shedding or
downmodulation on target cells (22, 24–27). A distinct pattern of NCR expression and
induction associates with a benign course of HIV infection in a minority of HIV-infected
patients with low or undetectable viremia (HIV controllers [HIC], long-term nonpro-
gressors [LTNP], and elite controllers [EC]) (28–30) and in chronically hepatitis C virus
(HCV)-infected patients who respond to treatment (31, 32). In addition, epidemiological
DNA carriage studies showed an association between speciﬁc KIR:HLA carriage and
control of HIV-1 replication (33–35). The impact of coordinate KIR:HLA genotype
carriage on disease progression so far partly eludes understanding due to the variability
of molecule transcription and surface expression on T and NK cells. Accordingly, the in
vitro effect of HLA:KIR carriage on NK cell control of HIV replication (HIVp24) in patients
with delayed disease progression remains controversial (36, 37). During infections with
different viruses, including human cytomegalovirus (HCMV) (38, 39), murine CMV
(MCMV) (40), and possibly chikungunya virus, dengue virus, and hantavirus (41, 42),
persistent or transient expansions of a speciﬁc NK cell subset bearing NKG2C in humans
and its homolog in mice have been described. These cell expansions are interpreted as
possible memory-like features of NK cells with resemblance to adaptive immune T cell
responses (11, 12).
With regard to NK cells in HIV-1 infection, scientiﬁc focus has so far concentrated on
their control of HIV-1 replication and of plasma viral load (RNA), leading, among other
achievements, to the identiﬁcation of particular KIR:HLA haplotypes or NCR expression
regulation that may control virus replication (30, 33, 37) and to their cooperation with
adaptive CD8 cytotoxic T lymphocyte (CTL) responses. The hallmark of lentivirus
infection is, however, represented by the persistence of integrated or partly episomal
DNA in long-lived cells—referred to as reservoir—which guarantees lifelong infection
(43).
Focuses on different reservoir sites and cells, including CXCR5 PD1 Tfh cells (44,
45), CD32 CD4 T cells (46), and tissue monocytes/macrophages, are currently being
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actively pursued. Peripheral blood HIV-1 DNA in circulating CD4 T cells represents an
acknowledged site for estimating the total HIV reservoir in HIV-infected patients (43,
47–49). The reservoir is still detected even after 5 to 14 years of successful (i.e., with
undetectable plasma viral RNA) antiretroviral therapy (ART) (50, 51). Persistence of HIV
DNA is maintained in a relatively constant nonreplicating pool of central memory CD4
T cells in peripheral blood, lymph nodes, and gut-associated lymphoid tissue (GALT)
(49) and in monocytes and follicular dendritic CD4 T cells (43). Quantitative determi-
nation of HIV DNA in peripheral blood mononuclear cells (PBMC) contributes to
deﬁning the risk of disease progression in infected patients (52), in whom low levels of
HIV DNA in CD4 PBMC are associated with nonprogressive disease (HIC) (53) with
posttreatment control of viremia (54). Accordingly, one of the major therapeutic
objectives for lentiviruses in general and HIV-1 in particular is represented by the
containment of the HIV DNA reservoir size and its targeting with novel therapeutic
strategies (55).
Limited information is available so far on the mechanism(s) that contributes to the
containment of the HIV-1 reservoir in vivo. To address this issue with a speciﬁc focus on
innate immune cells, we studied the relationship between NK cell function and total
and integrated HIV DNA copy numbers in circulating CD4 PBMC in two widely
diverging clinical cohorts (HIC and progressor patients). We report here that the
degrees of inducibility of interferon gamma (IFN-) production and NCRs have a linear
relationship to quantitative control of the HIV-1 reservoir in infected patients over a
wide spectrum of disease activity and are associated with a speciﬁc NK cell transcrip-
tional signature.
RESULTS
IFN- production by NK cells is associated with control of HIV DNA. We ﬁrst
studied the quantitative HIV-1 reservoir in circulating PBMC of progressor patients (PP)
who had been treated successfully and were persistently suppressed for 18 months
on ART and in a cohort of HIV-1 controller patients (HIC) with spontaneously stable
CD4 counts of 500/l and low or undetectable plasma viremia. As expected, a
higher viral reservoir was detected in PP than in HIC (Fig. 1A to C) in terms of total,
integrated, and unintegrated (i.e., linear DNA and 1- and 2-long-terminal-repeat [LTR]
circles) viral DNAs (P  0.001). In contrast, the evaluation of 2-LTR DNA was not
different between the two patient groups (Fig. 1D). A relatively wide range of numbers
of HIV-1 DNA copies/105 CD4 PBMC was detected in PP but also in HIC, suggesting
that ample variations possibly exist in the mechanism(s) underlying control of the HIV
reservoir in vivo both across patient groups (i.e., HIV versus PP) and within relatively
select groups, such as HIC. We therefore next sought to study possible parameters that
FIG 1 HIV DNA in PBMC from patients with different disease courses. Comparisons of total (A), integrated (B), unintegrated (C), and 2-LTR (D) HIV DNAs
(copies/105 CD4 cells) in HIC (EC and LTNP) (white boxes) and PP (gray boxes) are shown. For box plot analysis, bars represent ranges, lines represent median
values, and the box tops and bottoms represent the 75th and 25th percentiles, respectively (P  0.001 or P  0.0001 by the Mann-Whitney U test). HIC, HIV
controllers (n  20); PP, progressor patients (previously progressing patients who are successfully treated and have persistently undetectable HIV RNA [50
copies/ml]) (n  10).
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could be associated with and explain the wide dispersion of the HIV-1 reservoir
observed in HIC. In view of the reported association of innate NK cell control with virus
replication for HIV (30, 37) and the absence of an association of adaptive CD8 CTL
function with posttreatment control or HIC (56), we next studied whether circulating
HIV DNA levels could be associated with speciﬁc differences in NK cell function.
To this end, HIV DNA copy numbers in PBMC (expressed as numbers/CD4 PBMC)
were ﬁrst compared to NK cell IFN- levels by Spearman’s rho. NK cells were gated as
shown in Fig. 2. Lower HIV DNA loads were detected in patients with larger proportions
of IFN--producing NK cells. This signiﬁcant inverse association was detected using all
three NK cell-triggering strategies and was not restricted to a single activating stimulus
(Table 1; Fig. 3A to C). Representative examples of two HIC patients with different
proportions of NK cells producing IFN- and highly diverging HIV DNA reservoirs (8
versus 122 copies/105 CD4 cells) are shown in Fig. 3D and E. Data relevant to these two
divergent patients are outlined in Fig. 3A to C by open diamonds and open triangles,
respectively. Nonparametric correlation analysis showed a signiﬁcant correlation for
total and integrated DNAs but not for unintegrated DNA (Table 1).
Taken together, these data indicate that the size of the HIV DNA reservoir is closely
associated with the ability of NK cells to produce IFN- in response to multiple
triggering signals mimicking signaling of NCR-ligand recognition on target cells (e.g.,
B7-H6 through NKp30 or PVR/Nectin-2 via DNAM-1) or signaling by mature dendritic
cells (DCs) (e.g., DNAM-NKp30 or recombinant human interleukin-12 [rhIL-12]/rhIL-15).
The overall ability to produce IFN- contributes to up to 10-fold differences (as
indicated by the HIV DNA range) (Fig. 1A and B) in the control of the lentivirus reservoir
even among a homogeneous cohort of HIC patients with excellent control of viral
replication.
Inducible expression of NKp46 and NKp30 upon NK cell activation correlates
with HIV DNA reservoir and with IFN- production. We next studied whether
inducible NCR expression by NK cells, which has been associated with benign disease
courses in different chronic infections (tuberculosis [TB] [57], HCV infection [31], and HIV
infection [30, 58]), can also contribute to control of the size of the virus reservoir. To this
end, ﬂow cytometric analysis of NCR expression was performed on highly puriﬁed NK
FIG 2 Gating strategy for selection of NK cells. (A) Gating strategy for NK cell identiﬁcation, analysis, and sorting among PBMC. (B) Gating strategy for
identiﬁcation and characterization of PBMC-derived, puriﬁed NK cells in vitro after activation in vitro.
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TABLE 1 Nonparametric analysis of correlation of quantitated HIV DNA (total, integrated, or unintegrated) with IFN- production and
with activating receptor-induced expression on NK cells after activation in vitroa
Graphic representation,
data set Variable 1 Variable 2 Spearman  P > ||
Fig. 2 IFN-  (a) I HIV DNA 0.4858 0.0088*
IFN-  (b) I HIV DNA 0.5101 0.0013*
IFN-  (c) I HIV DNA 0.5831 0.0002*
Fig. 2, NS IFN-  (a) T HIV DNA 0.5976 0.0013*
IFN-  (b) T HIV DNA 0.4329 0.0190*
IFN-  (c) T HIV DNA 0.4148 0.0486*
IFN-  (a) U HIV DNA 0.2274 0.2851
IFN-  (b) U HIV DNA 0.0446 0.8286
IFN-  (c) U HIV DNA 0.0887 0.7098
Fig. 3A FI % NKp46 expression I HIV DNA 0.5536 0.0075*
FI % NKp30 expression I HIV DNA 0.6873 0.0033*
Fig. 3B IFN-  (a) FI % NKp46 expression 0.7169 0.0130*
FI % NKp30 expression IFN-  (a) 0.7945 0.0035*
Fig. 3C I HIV DNA FI MFI for NKp46 expression 0.6561 0.0205*
I HIV DNA FI MFI for NKp30 expression 0.6333 0.0365*
IFN-  (a) FI MFI for NKp46 expression 0.8389 0.0024*
IFN-  (a) FI MFI for NKp30 expression 0.7939 0.0061*
Fig. 3, NS FI % NKp46 expression T HIV DNA 0.6423 0.0032*
FI % NKp30 expression T HIV DNA 0.6527 0.0039*
FI % NKp46 expression U HIV DNA 0.056 0.7117
FI % NKp30 expression U HIV DNA 0.1989 0.1956
T HIV DNA FI MFI for NKp46 expression 0.6555 0.0207*
U HIV DNA FI MFI for NKp46 expression 0.487 0.0657
T HIV DNA FI MFI for NKp30 expression 0.6872 0.0195*
U HIV DNA FI MFI for NKp30 expression 0.5612 0.0724
Fig. 4A IFN-  (a) I HIV DNA 0.6048 0.0003*
IFN-  (b) I HIV DNA 0.4375 0.0053*
Fig. 4B FI % NKp46 expression I HIV DNA 0.5954 0.0056*
FI % NKp30 expression I HIV DNA 0.831 .0001*
Fig. 4C IFN-  (a) I HIV DNA 0.7185 0.0127*
IFN-  (b) I HIV DNA 0.7219 0.0121*
Fig. 4D FI % NKp46 expression I HIV DNA 0.0251 0.9489
FI % NKp30 expression I HIV DNA 0.2523 0.5852
Fig. 4F FI % NKp30 expression % cytolysis 0.7107 0.0142*
Fig. 4, NS IFN-  (a) T HIV DNA 0.5976 0.0013*
IFN-  (b) T HIV DNA 0.4329 0.0190*
FI % NKp46 expression T HIV DNA 0.5051 0.0231*
FI % NKp30 expression T HIV DNA 0.5258 0.0250*
IFN-  (a) T HIV DNA (only PP) 0.7165 0.0059*
IFN-  (b) T HIV DNA) (only PP) 0.8988 0.0001*
FI % NKp46 expression T HIV DNA (only PP) 0.0418 0.9149
FI % NKp30 expression T HIV DNA (only PP) 0.1441 0.7578
IFN-  (a) U HIV DNA 0.2274 0.2851
IFN-  (b) U HIV DNA 0.0446 0.8286
FI % NKp46 expression U HIV DNA 0.2325 0.324
FI % NKp30 expression U HIV DNA 0.3976 0.114
IFN-  (a) U HIV DNA (only PP) 0.1215 0.7219
IFN-  (b) U HIV DNA (only PP) 0.4014 0.221
FI % NKp46 expression U HIV DNA (only PP) 0.1187 7611
FI % NKp30 expression U HIV DNA (only PP) 0.3964 0.3786
NKG2D expression on resting NK cells I HIV DNA 0.1258 0.4518
NKG2D expression on resting NK cells T HIV DNA 0.1832 0.2516
NKG2D expression on resting NK cells U HIV DNA 0.0519 0.7603
aNS, not shown; I, integrated DNA; T, total DNA; U, unintegrated DNA; IFN-  NK, % CD56 IFN- NK cells; FI, fold increase; (a), after rhIL-12-plus-rhIL-15 activation; (b), NK
cells after anti-NKp46 and anti-NKp30 MAb activation; (c), after anti-NKG2D and DNAM-1 activation. HIV DNA was reported as the number of copies/10e4 CD4 cells. Group
composition refers to the group comparison in the respective ﬁgure (indicated in column 1), unless otherwise speciﬁed. Asterisks in the ﬁnal column indicate ●●●●.
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cells before and after rhIL-2 activation (see Fig. 2 for the gating strategy). The induc-
ibility of NCRs (Fig. 4E), expressed as the fold increase over baseline (see Materials and
Methods), was then correlated with the number of HIV DNA copies. As shown in Fig. 4A
and C and Table 1, the inducibility of both NKp46 and NKp30, expressed as proportions
of expressing cells and also as molecule density (mean ﬂuorescence intensity [MFI]) on
NK cells, was inversely correlated with the amount of HIV DNA (number of copies/105
CD4 PBMC) detected in PBMC from HIC patients (P 0.01 and P 0.001, respectively).
Similar correlations were detected for total HIV DNA but not for unintegrated DNA
(Table 1). No correlation was observed between NKp44 inducibility and reservoir size
(Fig. 4A).
Analysis of IFN- production and NCR induction upon NK cell activation revealed
that these two NK cell functions are directly correlated. Indeed, by inducing in vitro
activation with rhIL-12 plus rhIL-15—i.e., a condition independent of NCR triggering
and a proxy for NK cell activation by mature DCs—we detected a direct correlation
between IFN- secretion and de novo expression of NKp46 and NKp30 (P  0.01 and
P  0.05, respectively) (Fig. 4B and D).
Thus, these ﬁndings indicate that the size of the lentivirus reservoir in a subset of
patients with efﬁcient control of virus replication (HIC) correlates inversely with the
functional efﬁciency of NK cells in terms of not only IFN- production but also inducible
expression of NKp46 and NKp30.
NK cell function is associated with control of HIV DNA in PBMC with divergent
disease courses. The inverse association between two distinct NK cell functional
capabilities and the size of the HIV DNA reservoir in HIC raised the question of whether
FIG 3 HIV DNA is inversely correlated with induced IFN- production in NK cells from HIC. (A to C) Linear correlation analysis of quantitated integrated HIV DNA
(copies/105 CD4 cells) and puriﬁed NK cell IFN- production upon triggering with activating receptors or cytokines. (A) Anti-NKp46 and anti-NKp30. Data are
representative for 17 patients. (B) Anti-NKp30 and anti-DNAM-1. Data are representative for 16 patients. (C) rhIL-12 plus rhIL-15. Data are representative for 12
patients. (D and E) Flow cytometric analysis of peripheral NK cells producing IFN- from two patients with widely diverging HIV DNA copy numbers (marked
with open diamonds and open triangles in panels A to C), i.e., high (D) and low (E) HIV DNA copy numbers. CD3 cells were gated by ﬂow cytometric analysis
and analyzed for CD56 and CD16 expression and for intracellular IFN- production.
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this could be applied only to the minority (0.5 to 2%) of patients with exceptionally
conserved NK cell function (HIC) or if it could represent a general mechanism also
applying to patients who do not control HIV-1 replication and have progressive disease,
CD4 T cell loss, and the need for ART (PP).
To address this question, we analyzed NK cell function (IFN- production and
induction of NCR expression) in a group of stably virologically suppressed PP on
combination ART (cART). HIV DNA levels in PBMC from these patients were signiﬁcantly
higher than HIV DNA levels in the PBMC of HIC patients (17 versus 10 copies/105 CD4
PBMC; P  0.0001 by the U test) (Fig. 1).
Analyses of pooled (PP plus HIC) patient samples conﬁrmed the inverse relationship
between NK cell function and HIV DNA copies (Table 1). This correlation was detected
for both IFN- production (Fig. 5A) and induction of NKp46 and NKp30 expression
versus HIV DNA copies in PBMC (Fig. 5B). Following pooled analysis, PP samples were
FIG 4 Induced NCR expression by NK cells is inversely associated with the HIV DNA reservoir and correlates with IFN- production. (A) Integrated
HIV DNA copy numbers are inversely correlated with the fold increase in NKp46 or NKp30 expression on puriﬁed NK cells after in vitro activation
with rhIL-2 in HIV controller patients. (B) Peripheral NK cell IFN- production is directly correlated with the fold increase in NCR (NKp46 and NKp30)
expression on puriﬁed activated NK cells in HIV controller patients. The graphs show correlation analysis of NK cells producing IFN- in response
to cytokine stimulation (rhIL12rh-IL-15) and fold increases of NKp46 and NKp30 expression on puriﬁed NK cells after in vitro activation with
rh-IL-2 (n  12). (C) The HIV DNA reservoir in HIC (n  12) is inversely correlated with fold increase of NCR molecule density, expressed as MFI,
on puriﬁed NK cells after in vitro activation with rh-IL-2. Molecule densities are expressed as ratios of sample MFI to control MFI to account for
intersample variability (P 0.01). (D) Peripheral NK cell IFN- production in response to cytokine stimulation (rhIL-12/rhIL-15) is directly correlated
with fold increases of NKp46 and NKp30 molecule density, expressed as MFI, on puriﬁed NK cells after in vitro activation with rhIL-2 (P  0.01).
Data are representative for 12 different patients. (E) Representative shifts in NKp46 and in NKp30 molecule expression and density after
stimulation with rIL-2 in vitro for highly puriﬁed NK cells in former progressor patients after 24 month of successful cART (PP) and in HIV controller
patients (HIC). The graphs show the results of ﬂow cytometric analysis and overlay histogram representations. Light gray histogram, negative
control; dark gray histogram, resting cell NCR (NKp46 and NKp30) expression; red histogram, NCR expression after 48 h of culture in the presence
of rIL-2 200 IU/ml.
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also evaluated alone. As with HIC (Fig. 4), an inverse relationship was observed between
virus reservoir size and IFN- production (Fig. 5C), while this was not the case for NCR
inducibility (Fig. 5D). This was not unexpected, as a lack of NKp46 and NKp30 NCR
inducibility (but not NKp44 inducibility) is a hallmark of previously progressive disease
even after successful cART (30).
Since expression of NCRs is clearly inducible only in HIC, not in PP, we veriﬁed
whether differences in cytotoxic activity would actually reﬂect differences in activating
surface receptor expression after in vitro activation of puriﬁed NK cells. Indeed, levels of
NCR-mediated redirected killing of target cells were similar for HIC and PP at baseline
(freshly drawn puriﬁed NK cells; T0), while they were signiﬁcantly increased in HIC
versus PP after 2 and 4 days of in vitro activation in the presence of IL-2 (P 0.01), with
2- to 10-fold increases over baseline values for different patients (Fig. 5E). Interestingly,
NK cell cytotoxicity after activation in vitro directly correlated with the fold increase in
NCR expression (Fig. 5F). It should be noted that the differences observed in functional
induction of NCRs did not correspond to differences in baseline expression of the
NKp30, NKp46, or DNAM-1 activating receptor on NK cells (Fig. 6A; see Fig. 2 for the
FIG 5 NK cell function inversely correlates with HIV DNA reservoir size across widely divergent disease courses. (A) Linear correlation analysis of
integrated HIV DNA with IFN- production by NK cells triggered by activating receptors (NKp46 and NKp30) (n  27) or by cytokines (rhIL-12 plus
rhIL-15) (n  27) in HIC (dots) and PP. (B) Correlation analysis of integrated HIV DNA and fold increases of NCR (NKp46 [n  21] and NKp30 [n 
19]) expression on puriﬁed NK cells after in vitro activation with rhIL-2 in HIC (dots) and PP (x). Data are representative of 21 experiments. (C)
Correlation analysis for PP alone (x) of integrated HIV DNA and IFN- production by NK cells triggered by activating receptors (NKp46 and NKp30)
(n  10) or by cytokines (rhIL-12 plus rhIL-15) (n  10). (D) Correlation analysis for PP alone (x) of integrated HIV DNA and fold increases of NCR
(NKp46 [n  9] and NKp30 [n  7]) expression on puriﬁed NK cells after in vitro activation with rh-IL-2 (n.s., not signiﬁcant). (E) Puriﬁed NK cell
cyototoxicity before and after 2 and 4 days of in vitro activation in the presence of rhIL-2 (200 U/ml). A PKH-26/TO-PRO3 ﬂow cytometric
cytotoxicity assay was performed. Box plots indicate the percentages of target cell lysis in the presence of NKp30-speciﬁc MAbs in HIC (n  14)
and PP (n  7). In the box plots, bars represent range, lines represent median values, and box tops and bottoms represent 75th and 25th
percentiles, respectively (P  0.01 by the Mann–Whitney U test). (F) Correlation analysis of NK cell cytotoxicity and NKp30 induction upon in vitro
rhIL-2 activation in HIC (n 6) and PP (n 5). HIC, HIV-controller patients; PP, progressor patients who were aviremic and needed cART to control
viral replication.
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gating strategy), and the frequencies of NKp30 and NKp46 NK cells did not
correlate with IFN-y production. In addition, IFN-y production inversely correlated
with the reservoir size not only under conditions with NK cell triggering via NKp46/30
but also via IL-15/IL-12 and NKp30/DNAM-1 triggering. These ﬁndings indicate that the
key functional feature with regard to IFN-y production is not represented by basal
receptor expression but rather by intrinsic production upon polyfunctional triggering.
With regard to NKG2D, its expression was increased in HIC compared to that in
healthy donors (HD) (Fig. 5A), with comparable IFN- production upon its triggering in
combination with DNAM-1 to reproduce the interaction with DCs in vitro (Fig. 6B). No
defect emerged in the general potential of NK cells from PP to produce IFN- compared
to that of cells from HD, as determined following maximal stimulation with phorbol
myristate acetate (PMA) plus ionomycin (Fig. 6C), and HIC had increased IFN--
producing potential compared to both PP and HD (Fig. 6C).
Thus, these results show that inducibility of NCR expression parallels acknowledged
important NK cell functions, such as IFN- production, and contributes to editing
downstream NCR-mediated NK cell cytotoxicity. The relationship of these functional
activities with quantitative HIV DNA assessment independent of the ability to control
HIV-1 replication and CD4 cell loss suggests that different set points for the virus
reservoir (HIV DNA) are associated with a continuum of quantitative NK cell functions.
The satisfactory control of HIV DNA copies observed not only in HIC but also in some
PP after successful ART suggests a preferential role for in vivo NK cell function in the
control of the lentivirus burden (DNA) even when failing to control the viral load/
replication (RNA).
Distinct NK cell transcriptional signatures underlie the control of reservoir size.
Upon the identiﬁcation of IFN- production and the extent of NCR (NKp46 and NKp30)
modulation as inverse correlates of HIV reservoir size in CD4 PBMC, we decided to
address some open questions, including whether the strong correlations observed
could indeed be based on substantial differences in transcriptional programs. We
wanted to test the possibility that increased transcripts for NKp46 (NCR1) and NKp30
(NCR3) could be detected, or rather whether the increased de novo expression of NCR
in NK cells from HIC patients would depend predominantly on posttranscriptional
regulation. In addition, we also wanted to explore additional differences in transcrip-
FIG 6 Baseline expression of activating receptors on NK cells and IFN--producing potential under NKG2D
and DNAM-1 triggering and under maximal stimulation. (A) Flow cytometric analysis of peripheral NK cells in HD
(white), HIC (light gray), and PP (dark gray). (B and C) IFN- production by NK cells upon NKG2D- and
DNAM-1 triggering (B) or via PMA and ionomycin (C). For box plot analysis, bars represent ranges, lines
represent median values, and box tops and bottoms represent 75th and 25th percentiles, respectively (P 
0.05 or P  0.001 by the Mann–Whitney U test). HD, healthy donors (n  10); HIC, HIV controller patients
(n  20); PP, progressor patients (n  10).
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tional signatures that could help to identify speciﬁc surface markers for future selection
strategies.
To this end, we performed a full transcriptional characterization of puriﬁed periph-
eral NK cells. Multiple samples of puriﬁed NK cells, either resting or activated in vitro
with rhIL-2, were obtained from different patients (4 HIC and 4 PP) and evaluated by
microarray analysis. Comparative transcript analysis (Student’s t test cutoff, P  0.05)
identiﬁed 370 genes which were differentially expressed by puriﬁed resting NK cells
derived from HIC and PP (Fig. 7A). Interestingly, a set of 370 transcripts were also found
to be differentially expressed in NK cells of HIC versus PP following rhIL-2 stimulation
(Student’s t test cutoff, P  0.05) (Fig. 7B). By assessing the identities of the transcripts
that were differentially expressed under resting and activated conditions, however,
only 5 genes were found to be overlapping between the two sets of 370 transcripts
(Fig. 7C). In NK cells derived from HIC patients, of the 370 genes differentially expressed
upon rhIL-2 stimulation, 306 (see Table S1 in the supplemental material) and 64 (Table
S2) were upregulated and downregulated, respectively. Interestingly, genes encoding
activating receptors of NK cells, such as NCR3 (NKp30) and NCR1 (NKp46), were found
to be upregulated in NK cells derived from HIC patients upon rhIL-2 stimulation (Table
S1), thus indicating that in NK cells from these patients, NCR induction is transcription-
ally regulated and differs from that in PP. Under the same conditions, other transcripts
coding for activating NK cell receptors were also upregulated, including NKG2D
(KLRK1), NKG2F (KLRC4), and NKp80 (KLRF1), while transcripts coding for an inhibitory
receptor (CTLA4) were downregulated. Transcripts for NKG2C (KLRC2) showed only a
trend toward increased transcription (P  0.17; fold increase  2.5). In addition,
signiﬁcantly increased expression of the inhibitory receptor transcripts KIR2DL4 and
KIR3DL3 was detected at baseline for HIC compared to that for PP. At the same time,
the induction of KIR3DS1 conﬁrmed previous reports (37) and may contribute to HIV
DNA control only in the fraction of HIC carrying the appropriate HLA class I molecules.
We then explored the functional pathways among the differentially expressed
transcripts by FunRich analysis. The entire cohort of 370 transcripts that were differ-
FIG 7 Whole-genome microarray analysis demonstrates the existence of differential gene expression patterns of NK cells between HIC and PP. (A) Heat map
based on genes differentially expressed HIC versus PP (P  0.05 by the Student t test and fold change of 1.5) (370 genes for time T0). (B) Heat map based
on genes differentially expressed in HIC versus PP (P  0.05 by the Student t test and fold change of 1.5) (370 genes for time T4). (C) Venn diagram showing
genes in common between T0 and T4. (D) Gene Ontology enrichment analysis of puriﬁed NK cells by FunRich. Biological pathways overrepresented in genes
differentially expressed in HIC versus PP are shown. T0, resting NK cells; T4, NK cells after 4 days of IL-2 culture; HIC, HIV controller patients (n 4); PP, progressor
patients (n  4).
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entially expressed between HIC and PP following rhIL-2 stimulation showed an involve-
ment of IFN-, rhIL-2/rhIL-12, and tumor necrosis factor (TNF) receptor signaling
pathways (Fig. 7D). Furthermore, functional analysis performed by use of the David tool
showed that genes that were upregulated in HIC upon rhIL-2 stimulation (n  306)
were mostly involved in the NF-B pathway, in lysosome signaling, and in mechanisms
shared with lymphocyte cytotoxicity (Table S3).
The different transcriptional signatures of puriﬁed NK cells in HIC may reﬂect an
inherent, and possibly genetically encoded, regulation of NK cell function, or rather
may derive from a memory-like expansion of one or a few NK cell subsets following
persistent lentiviral infection. Both the NKG2C activating receptor and CD57 are ex-
pressed on CD56dim memory-like NK cells that undergo expansion after HCMV and
other virus infections (39, 40). Therefore, we studied the expression of these markers on
NK cells from our patient cohorts. In line with the KLRC2 ﬁndings by microarray analysis,
ﬂow cytometric analysis of peripheral NK cells from HIC and PP showed similar
proportions of memory-like NK cells (HIC versus PP) in terms of both CD56dim NKG2C
and CD56dim CD57 NKG2C NK cells, while these were virtually absent in HD, as
expected, due to a lower CMV seroprevalence (Fig. 8). Taken together, these results
show that differences in major NK cell functional activity in patients who control the
lentiviral reservoir (HIV DNA) rely on inherent NK cell transcriptional regulation, with a
distinctive signature involving primarily several activating NK cell receptors. Thus, an NK
cell enrichment that is sufﬁciently high to be detected clearly by macroarray analysis is
present. This was unrelated to differential involvement in HIV-1 reservoir control of
the whole subset of memory-like (NKG2C CD57) NK cells. However, the possibility
cannot be discarded that a particular subset of cells in this memory-like population may
be involved and may encompass adaptive NK cells with inducible NCR/NKG2D/NKp80,
as indicated by in vitro and microarray analyses.
Transcriptionally unique NK cells from HIC patients control HIV integration in
CD4 T cells in vitro. In order to directly verify that differences in NK cell function and
signiﬁcant differences in transcriptional signature indeed determine different DNA
integration statuses and contribute to the lentivirus reservoir size, we then studied the
effect of coculturing NK cells in an in vitro infection experimental model.
Puriﬁed activated HD CD4 blasts were cultured in vitro and infected with HIV-1Bal
at a high multiplicity of infection (MOI  0.1). After removal of excess virus, highly
puriﬁed (98%) activated NK cells from patients were added to the cultures at a 0.5:1
(NK:CD4) cell ratio. This experimental design aimed at studying in vitro control of the
FIG 8 NK cells from HIC and PP show similar proportions of memory-like NK cells. CD3 CD14 CD19 cells were gated by
ﬂow cytometric analysis and analyzed for CD56 and NKG2C/CD57 expression in HD (white), HIC (gray), and PP (black). In the
box plots, bars represent ranges, lines represent median values, and box tops and bottoms represent 75th and 25th
percentiles, respectively (P  0.05 or P  0.01 by the Mann-Whitney U test). Data are representative of 30 experiments. HD,
healthy donors (n  10); HIC, HIV controller patients (n  10); PP, progressor patients (n  10).
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DNA reservoir by NK cells while monitoring successful infection as represented by HIV
RNA/p24. To explore the effects of predominant IFN- production and NCR expression
on infected CD4 cells and to minimize the physiological inhibitory effect of KIR:HLA
engagement, preactivation of puriﬁed NK cells was performed before coculture in an
allogeneic system.
Virus replication, as measured by numbers of supernatant RNA copies and by HIV
p24 expression by infected CD4 T cells, peaked at day 7 after infection. NK cells from
HIC patients efﬁciently controlled virus replication compared to those from PP (Fig. 9A
and B). An 88% reduction of p24 CD4 T cells was detected in culture by ﬂow
cytometry, and a 93% reduction in HIV RNA was detected by quantitative reverse
transcription-PCR (qRT-PCR). Quantitative evaluation of HIV DNA was performed by
RT-PCR and showed that HIC NK cells sharply controlled total and integrated HIV-1 DNA
accumulation during peak virus replication, with 98% and 96% reductions in total and
integrated HIV DNAs, respectively, compared to the levels in cultures supplemented
with puriﬁed NK cells from PP (Fig. 9C and D). In comparing the effects of NK cells from
different donors (HIC versus PP) on HIV DNA accumulation (Fig. 9E), puriﬁed HIC NK
cells with speciﬁc transcriptional signatures had a 35-fold larger effect than that of NK
cells from PP (Fig. 9F). A more contained comparative potency in containing HIV-1
replication was observed (14- and 8-fold for HIV RNA and HIV p24, respectively) (Fig. 9F).
Compared to NK cells from PP, lacking NCR and IFN- inducibility, the presently
characterized NK cells, with a characteristic function and transcriptional signature, had
an approximately 3-fold higher efﬁcacy in containing HIV DNA accumulation over HIV
replication.
Taken together, these experiments show that NK cells with a speciﬁc transcriptional
signature and function provide a remarkable contribution to limiting HIV DNA in vitro,
thus conﬁrming the in vivo observations.
FIG 9 Puriﬁed NK cells from HIC patients control HIV integration in vitro. IL-2/PHA CD4 T lymphocytes were infected with HIV-1Bal at an MOI of 0.01 in the
presence or absence of activated NK cells from PP or HIC. After 7 days of culture, virus replication was monitored by measuring HIV RNA (copies per milliliter)
in the supernatant (A), p24 levels via intracellular staining of CD356 T cells by ﬂow cytometry (B), and viral reservoir accumulation by quantitative assay of
total HIV DNA (copies/105 CD4 cells) (C) and of integrated HIV DNA (D). (E) Fold decreases in virus accumulation in the presence of the given puriﬁed NK cells
over that in control cultures without NK cells. (F) Relative potencies of puriﬁed NK cells from HIC versus NK cells from PP in inhibiting virus replication or DNA
integration/accumulation. HIC, HIV controller patients (n  6); PP, progressor patients (n  6).
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Control of the DNA reservoir, rather than only RNA, represents the main goal for the
treatment of lentiviruses, and ultimately for retrovirus eradication and clearance (43,
58–60). However, the immune mechanism(s) contributing to lentivirus DNA reservoir
size shaping and control still eludes our full understanding. NK cells are involved in the
control of RNA and DNA viruses belonging to different virus families, including the
control of retrovirus replication (11, 16, 32, 38, 61).
In the present work, we explored the impact of NK cell function and NK cell
characterization on the containment of the lentivirus reservoir in vivo and in vitro by
using HIV-1 as a model. The results provide evidence that transcriptionally character-
ized NK cells substantially contribute to HIV reservoir containment. The induction of
IFN- and NCR (NKp46 and NKp30) expression represents a quantitative functional
correlate of lentiviral reservoir size containment. Previous work showed that NK cells
with speciﬁc HLA:KIR carriage may control viral replication (RNA production) without
information on the HIV reservoir (37) and also that nonprogressing disease may be
unrelated to carriage of KIR3DS1 (36). In the present in vivo and in vitro settings, no
HLA:KIR carriage was associated with HIC status, and the in vitro experimental strategy
was chosen to minimize the interference of HLA:KIR interaction with NCR expression/
inducibility and IFN- production on HIV DNA accumulation. A doubtless need has
emerged for future work to include combined analyses of activating and inhibitory NK
cell receptors and of the actual expression of KIR3DL1/3DS1 and of HLA-Bw4 and the
role of other soluble factors produced by NK cells in addition to IFN-.
The present ﬁnding of higher levels of HIV DNA in CD4 PBMC from cART-treated
PP is in line with previous reports (53) and with the association of more rapid disease
progression in patients with higher CD4 T cell-associated circulating HIV DNA (52). In
fact, the reservoir size decays with shallower slopes after the ﬁrst year(s) of cART,
remains constant and fails to decrease below detectability in most patients (50, 51), and
is independent of CD8 CTL activity (51). Virus replication invariably resumes upon
cART interruption (47, 48, 50), with a remarkable exception to this concept being a very
small group of early cART-treated patients (posttreatment controller patients [PTCP]) (4,
5). The present ﬁndings on NK cell-associated control of HIV reservoir size provide a
novel reading frame for the above observations, suggesting that NK cell functional
potential in terms of NCR and IFN- inducibility represents two pivotal elements of
proviral DNA containment. Indeed, cART has a remarkable impact on HIV replication in
CD4 cells; however, it has limited effects on the recovery of NK cell function (62, 63)
and on DNA size reduction (51). An adaptive CTL-mediated control of DNA reservoir size
is unlikely, as suggested by the heterogeneity of CD8 CTL function in PTCP (64) and
by the lack of correlation between CD8 CTL activation and the DNA reservoir (51).
Thus, according to the present data, the failure to fully reconstitute NK cell function
upon cART in PP is likely to contribute to the limited decrease in HIV reservoir size over
time (50, 51), and ultimately to the renewed HIV replication observed upon treatment
interruption in most patients (47, 48). In view of the reported lack of CD8 CTL control
in PTCP, it may be hypothesized that, in these patients, NK cells may represent an
important immune mechanism leading to HIV reservoir and spontaneous posttreat-
ment control.
cART has been shown to reconstitute CD4 cell numbers, to leave NK cell pheno-
type and function largely unaffected, and to provide a minimal contribution to HIV
reservoir decrease. For this reason, it appears unlikely that the effects on HIV reservoir
size and NK cell function in treated patients are due to cART. It remains to be
determined whether some patients with active replication and progression to low CD4
numbers may still limit the reservoir size in the presence of robust innate immune
defenses (e.g., NK cell function) or whether, in some PP, cART may also be effective for
NK cell function and contribute to the HIV reservoir. Further focus is needed to
understand whether the NK cell function/transcriptional proﬁle is preset and innate or
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may be affected by virus replication or by cART and to what extent poor control of the
CD4 cell HIV reservoir by poor IFN- producers may be improved.
If conﬁrmed, the present characterization of transcriptionally and functionally dis-
tinctive NK cells may be exploited for the prospective identiﬁcation of HIV patients with
good chances of success for undergoing cART simpliﬁcation to monotherapy (65) or
cART interruption (e.g., PTCP) (58, 66, 67).
In the present analysis, NK cells controlling HIV-1 reservoir size displayed a set of 370
differentially expressed NK cell genes/transcripts that included, among others, the
principal functional NK cell pathways (i.e., cytokine production, cytokine response, and
NCR induction) that were assessed by phenotypic and functional assays. This indicates
that an inherent individual regulation of NK cell gene expression underlies functional
differences and affects the control of the HIV-1 reservoir set point and disease course
(52). This ﬁnding is in line with previous observations showing that the NK cell
transcriptional signature underlies speciﬁc disease courses in chronically HCV-infected
patients who respond to treatment (58, 68). In view of the considerable size of the NK
cell phenotype spectrum, with up to 30,000 to 100,000 phenotypes (13), the detection
of a specialized NK cell population of sufﬁcient size to identify a distinct transcriptional
signature may reﬂect enrichment of circulating NK cells, thus raising the question of
their origin. NK cell-mediated memory-like reactions with large expansions of NKG2C
CD57 NK cells have been detected during infections with different viruses in humans
(38, 42, 69) and in animal models (40). Enrichment of memory-like NK cells of known
phenotype (NKG2C CD57) was not involved here, since both patient groups (HIC and
PP) had similarly large circulating pools of putative memory-like (NKG2C CD57) NK
cells, while functional and transcriptional differences were detected only for patients
with the smaller lentiviral reservoir size (HIC). Support of the view that control of the
lentiviral reservoir cannot be ascribed to imbalances of the memory-like NK cell subset
as a whole is further provided by the efﬁcient IFN- production by NK cells upon
rhIL-2 or rhIL-12/rhIL-15 stimulation. This is in contrast to the diminished responses to
rhIL-12 and rhIL-18 in NKG2C NK cells from HCMV donors (42) and to reduced IFN-
production upon H1N1 inﬂuenza virus antigen or pertussis toxin stimulation (70).
Moreover, memory-like NK cell expansion in HIV patients is due to HCMV rather than to
persistent HIV-1 infection (71). Therefore, two possible hypotheses may be proposed to
explain our present ﬁndings. First, the enrichment in NK cells with such a distinct
transcriptional signature in patients with a small HIV-1 reservoir size may represent a
novel type of “trained” or adaptive NK cells, either independent of or representing a
specialized subset of “memory-like” NKG2C NK cells that is expanded and functional
in HIC but not in PP. These cells may be identiﬁed by their ability to induce transcription
of NKp46, NKp30, NKG2D, and NKp80 while retaining CD57 and NKG2C expression.
Alternatively, in agreement with the high environmental inﬂuence of NK cell activating
receptor expression (13), they may represent an inherent rather than an acquired
inborn feature, therefore predating HIV infection and contributing to lentiviral contain-
ment following virus entry. In this case, their expansion may be detected in the healthy
population at a low frequency (about 1 to 2%) superimposable to HIC prevalence
among HIV-infected patients. Further work is needed to fully identify the origin and the
presence at low frequency of these phenotypes in the overall population.
Finally, current programs and protocols for HIV eradication, including histone deacety-
lase inhibitor (HDACi) administration and immunotherapy, reportedly need improved
immunotherapeutic strategies to clear virus in reactivated cells and to limit new virus
integration (43, 55, 59, 72, 73). Selection and expansion of NK cells with high NCR and
IFN- inducibility may represent a useful tool to efﬁciently clear HIV-1 when combined
within the frame of virus eradication strategies exploiting latency exit induction and
immuno-/antiretroviral therapy (72–74).
In conclusion, HIV reservoir size is dependent on the presence of a deﬁned NK cell
population with a speciﬁc transcriptional signature: high NCR (NKp46 and NKp30) and
IFN- inducibility upon NCR and cytokine receptor engagement. These cells may
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represent a novel tool offering relevant promise for translational applications, including
patient monitoring, treatment interruption, and virus eradication.
MATERIALS AND METHODS
Patients. Five infectious disease units caring for HIV patients enrolled 20 HIV-1-infected controller
patients (10 EC and 10 LTNP) and 10 HIV-1-infected patients with progressive disease (Table 2). Patients
were being monitored within a program for surveillance and treatment of HIV-1 infection. EC patients
had positive HIV-1 serology, were ART naive, and had CD4 counts of 450 cells/l at all visits for 7
years of follow-up, with no clinical evidence of disease progression. LTNP met the same deﬁnitions as
those for EC, with the exception of HIV RNA being detectable during the years of observation, at 2,000
copies/ml. A group of HIV-infected progressor patients on ART with HIV RNA levels of 50 copies/ml for
at least 24 months and CD4 T cell levels of 350/l were considered aviremic progressor controls
(progressor patients [PP]). For these patients, evidence from clinical records at cART initiation showed
that they had viral replication and low CD4 cell numbers. HD (n  10) were recruited locally among
blood bank donors. Carriage of KIR:HLA alleles by HIC and PP was analyzed as described previously (30).
No signiﬁcant association for HLA-Bw4:KR3DL1/S1 was detected in HIC versus PP.
Exclusion criteria were current or previous ART, age of 18 years, pregnancy, cancer, and treatment
for HCV infection during the previous 6 months.
The study was authorized by the local ethical committee. Patients were enrolled after providing
informed consent. Peripheral blood mononuclear cells (PBMC) were obtained by density gradient
centrifugation (Ficoll-Hypaque) and processed or cryopreserved at 80°C.
Abs. The following panel of mouse anti-human monoclonal antibodies (MAbs) was used: PC7-
conjugated anti-CD56 (clone N901; Immunotech-Coulter), ﬂuorescein isothiocyanate (FITC)- and allophy-
cocyanin (APC)-conjugated anti-CD3 (clone HIT3A; BioLegend), APC-conjugated anti-CD19 and anti-CD14
(clones HIB19 and M5E2, respectively; BioLegend), phycoerythrin (PE)- and FITC-conjugated anti-CD16
(clone 3G8; BD Pharmingen), 7-aminoactinomycin D (7AAD) (BD Pharmingen), anti-NKp46 (BAB281 and
IgG1), anti-NKp30 (7A6 and IgG1), anti-NKp44 (ZIN231 and IgG1), anti-NKG2D (BAT221 and IgG1), and
anti-DNAM-1 (F22 and IgG1). FITC-conjugated (Southern Biotechnology) and PE-conjugated goat anti-
mouse anti-isotype Abs (BD Pharmingen) were used as controls.
Immunoﬂuorescence analysis. Cells were analyzed by eight-color ﬂow cytometry. Brieﬂy, cells were
incubated with primary MAbs followed by PE- or FITC-conjugated anti-isotype-speciﬁc goat anti-mouse
secondary reagents. Direct staining was performed by use of ﬂuorochrome-conjugated MAbs as the third
step. For cytoﬂuorimetric analysis, cells were gated using forward and side light scatter parameters
(FACSCantoII; BD), and 10,000 events were always acquired on CD3/14/19 CD56 gating. MFI was used
to quantify molecule density. To reduce interassay variability, the MFI ratio (MFIsample/MFIcontrol) was used
to compare samples/groups. Data were analyzed using FlowJo (Tree Star, Inc.). Gating strategies are
shown in Fig. 2.
NK cell activating receptor induction assay. NK cells were isolated from PBMC by negative
immunomagnetic separation using an NK cell isolation kit II (Miltenyi Biotec) as previously described (75).
NK cell purity was 95%.
NKp46, NKp30, and NKp44 expression on highly puriﬁed NK cells before and 2 and 4 days after in vitro
culture with rhIL-2 (200 U/ml) (Proleukin; Chiron Corp.) was analyzed by ﬂow cytometry. Receptor
expression changes were determined by comparing the MFI ratio to the fresh NK cell MFI ratio, as follows:
(MFIratio ACT  MFIratio baseline)/MFIratio baseline  100 (ACT stands for “activated”).
Cytotoxicity assay. NK cell cytotoxic activity was determined using a PKH26 and TO-PRO3 (Sigma-
Aldrich and Invitrogen, respectively) assay as previously described (76). FcR P815 mouse mastocytoma
cell lines were used as target cells and were labeled with PKH26 (76). P815-PKH26 cells were incubated
with rhIL-2-activated NK cells at a 1:1 effector:target (E:T) ratio. Cultures were incubated for 4 h at 37°C
in 5% CO2 in RPMI 1620 medium (BioWhittaker, Lonza) supplemented with 10% fetal calf serum (FCS)
(complete medium [CM]), in the presence or absence of MAbs, and then placed on ice until ﬂow
cytometric analysis. Spontaneous and maximal target cell deaths were determined by PKH26 labeling of
cells cultured alone and permeabilized with BD Cytoﬁx/Cytoperm reagent (BD Pharmingen), respectively.
To identify dead cells, 5 l of a 10 M stock solution of TO-PRO3 was added to each tube immediately
before analysis. Cells were analyzed by FACSCanto II ﬂow cytometry (BD), and 10,000 events were
collected. Speciﬁc lysis was calculated by use of the following formula for dye-labeled cells: (sample 
spontaneous)/(total  spontaneous)  100.
IFN- production assay. PBMC were stimulated using FcR P815 target cells at a 10:1 E:T ratio in
completemedium in the presence or absence of an anti-NKp30, anti-NKp46, anti-NKp30, and/or anti-DNAM-1









No. of CD4 cells
at baseline Last % CD4 cells Last CD4 count
Length of HIV
status (yr)
EC 52 4.41 3 7 35 6.59 1,033 479.8 35.8 5.07 739.5 347.6 20 4.4
LTNP 49 12.2 4 6 36 7.83 876 378 34.6 8.33 776 362 18 8.3
PP 51 5.9 4 6 9.9 5.56 85 75.5 24.6 8.33 325 182 17 4.9
aWith the exception of gender data, numbers represent means  SD.
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MAb mixture (0.1 g ml1), rhIL-12 (20 ng ml1), and rhIL-15 (40 ng ml1) (PeproTech), as previously
described (75).
HIV infection. PBMC from healthy HIV-1-seronegative donors were activated with puriﬁed phyto-
hemagglutinin (PHA) (0.25% [vol/vol]) and rhIL-2 (50 U/ml) for 5 days in RPMI 1620 complete medium
(BioWhittaker, Lonza) supplemented with 10% FCS, L-glutamine (2 mM), and a 1% antibiotic mixture
(penicillin-streptomycin [5 mg/ml]). Activated CD4 cells were positively puriﬁed by use of antibody-
coated magnetic beads (Miltenyi Biotec) and then cultured with rhIL-2 (50 U/ml) for 1 week. The cells
were infected with HIV-1 (HIVBal; a kind gift from G. Poli, Milan, Italy) at an MOI of 0.01 for 2 h at 37°C in
a humidiﬁed 5% CO2 atmosphere, washed twice to remove excess virus, and cultured (5  105 cells/ml)
in CM with rhIL-2 (50 U/ml) alone or with puriﬁed/activated NK cells in triplicate at a 1:2 ratio.
Supernatants and cells were collected on day 7 and cryopreserved.
Total, unintegrated, and integrated HIV DNA quantiﬁcation. DNAs were isolated from 1.0  106
to 2.0  106 PBMC from HIC and PP and from 3.0  105 in vitro-infected CD4 blasts. A constant
HIV-1-negative donor background of 1 107 uninfected and unstimulated PBMC was mixed with the cell
pellets to ensure high DNA extraction efﬁciencies. Brieﬂy, total and unintegrated HIV DNAs (the ensemble
of linear and 1- and 2-LTR circular DNAs) were selectively separated by an optimized chromatographic
procedure (a method utilized to separate the high-molecular-weight DNA containing the proviral HIV
DNA from the low-molecular-weight DNA, consisting of unintegrated HIV DNA) (77) and analyzed by
quantitative SYBR green I real-time PCR (qPCR), using a single set of speciﬁc primers selected in the
highly conserved LTR-Gag region of the HIV-1 genome (78) and able to detect all HIV-1 subtypes in the
M group. The qPCR measurements of 2-LTR circles were performed using primers ﬂanking the dual-
repeat cassette within the circular form. PCRs were carried out with a ﬁnal volume of 50 l in a model
7500 real-time PCR system (Applied Biosystems, Thermo Fisher Scientiﬁc Inc.), using an HIV-1 DNA qPCR
kit (Diatheva s.r.l., Fano, Italy) according to the above-developed assay. Each sample was analyzed in
triplicate in the ﬁrst PCR (1st qPCR), which consisted of two wells containing 0.5 g each plus one well
containing 1.0 g of DNA (to ensure the detection of the target even at a low copy number, i.e., near the
quantiﬁcation limit [QL] [2 copies/PCR]), or the equivalent quantity of elution fraction from chromato-
graphic separation to quantify unintegrated forms. For samples with HIV DNA values of 30 copies
(coefﬁcient of variation of 21%), a 2nd PCR experiment was performed. Six 0.5-g replicates were assayed
for samples which in the 1st qPCR had been quantiﬁed in the range of 2 to 30 copies; three 0.5-g
replicates and three 1.0-g replicates were tested for samples which in the 1st qPCR had been quantiﬁed
near or detected below the QL. In case of negative ampliﬁcation, a PCR spike test was performed by
adding 2 or 10 copies of our plasmid (pPBS) standard to the samples to exclude the presence of
inhibitors. The HIV-1 DNA copy number was estimated by interpolation of the experimentally determined
threshold cycle (CT) based on standard curves generated using half-log serial dilutions from 103 to 2
copies. The amount of integrated HIV DNA was obtained by subtracting the amount of unintegrated DNA
from the amount of total HIV DNA. The agreement between the indirect and direct measurements of
integrated HIV DNA has been demonstrated before (A. Casabianca, unpublished data). Total, uninte-
grated, integrated, and 2-LTR DNA copy numbers were determined by adding up the copy numbers from
the 0.5/1.0-g replicates tested and were expressed relative to 1 g of DNA and then normalized to
numbers of copies/105 CD4 T cells. Values of 2 copies/g were considered to have a value of 1 for
statistical analyses.
Serum and supernatant HIV RNA levels were quantiﬁed by use of a commercial kit according to the
manufacturer’s instructions (Nuclisens EasyQ HIV-1 2.0; bioMérieux SA).
Microarray analysis. Total RNA was puriﬁed from freshly isolated, puriﬁed (98%) NK cells after ﬂow
cytometric sorting for 4 HIC patients and 4 PP by use of miRNeasy minikits (Qiagen, Germantown, MD,
USA) according to the manufacturer’s protocol. RNA quality and quantity were estimated using Nano-
drop spectrophotometry (Thermo Scientiﬁc, Waltham, MA, USA) and an Agilent 2100 bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). First- and second-strand cDNAs were synthesized from 10 ng of total
RNA by use of a Nugen Ovation Pico WTA system V2 (Nugen Technologies, San Carlos, CA, USA) following
the manufacturer’s instructions. cDNAs were fragmented and biotinylated by use of the Nugen Encore
biotin module (Nugen Technologies, San Carlos, CA, USA) and hybridized to GeneChip Human Gene 1.0
ST arrays (Affymetrix, Santa Clara, CA, USA). The arrays were washed and stained on a GeneChip 450
ﬂuidics station and scanned by a GeneChip 3000 scanner (Affymetrix, Santa Clara, CA, USA). Global gene
expression proﬁling of NK cells was analyzed using Partek Genomics Suite (St. Louis, MO). Functional
analysis was performed using David analysis (https://david.ncifcrf.gov/) and FunRich analysis (functional
enrichment analysis tool).
Analysis of genetic carriage of HLA and KIR was performed on PBMC as previously described (30) and
failed to show signiﬁcant gene carriage enrichments.
Statistical analysis. Statistical analysis was performed using the Mann-Whitney U test for compar-
isons between unpaired data sets. Correlation analysis was performed by Spearman’s test and by
two-way direct correlation for graphical representation. Analysis was performed using JMP 10.0 (SAS).
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